Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche deal—review the catalysts, ...
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell ...
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that ...
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg ...
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into ...
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove ...
Dennis Rader, the BTK serial killer whose self-given nickname stands for “Bind, Torture, Kill,” played a cat and mouse game with investigators and reporters for decades before he was caught. But Rader ...
Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and ...
Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics. The licensing ...
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results